News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apricus Biosciences (APRI) Receives $2.5 Million Payment From Abbott Laboratories (ABT) for Vitaros® in Canada


10/18/2012 9:14:54 AM

SAN DIEGO, Oct. 18, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that it received a $2.5 million payment from Abbott Laboratories Limited ("Abbott") under its commercial partnership for Apricus Bio's VitarosĀ® drug for erectile dysfunction ("ED") in Canada. Also, Apricus Bio successfully produced six consecutive commercial size validation batches of VitarosĀ®, the Company's treatment for ED in 220 mcg and 330 mcg forms.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES